Sol-Gel TechnologiesSTU:4SG -2.36%55 Piotroski F-Score is 6 as of Jul. 04, 2026, which is 50% above its 10-year median of 4.00. GuruFocus rates STU:4SG with a GF Score™ of 55/100 and a GF Value™ of €54.63 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 1,336 Biotechnology companies, Sol-Gel Technologies ranks better than 91.99% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sol-Gel Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Sol-Gel Technologies's Piotroski F-Score or its related term are showing as below:
STU:4SG'
s Piotroski F-Score Range Over the Past 10 Years
Min: 1 Med: 4 Max: 6
Current: 6
During the past 11 years, the highest Piotroski F-Score of Sol-Gel Technologies was 6. The lowest was 1. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Sol-Gel Technologies Piotroski F-Score Related Terms
Sol-Gel Technologies Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Sol-Gel Technologies's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:4SG vs AVXL, FATE, FHTX: Piotroski F-Score Comparison
For the Biotechnology subindustry, Sol-Gel Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sol-Gel Technologies Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sol-Gel Technologies's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Sol-Gel Technologies's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Sol-Gel Technologies's current Net Income (TTM) was -5.23.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Sol-Gel Technologies's return on assets of this year was -0.15283498. Sol-Gel Technologies's return on assets of last year was -0.24330572.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Sol-Gel Technologies's gearing of this year was 0.01418487. Sol-Gel Technologies's gearing of last year was 0.0221222.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Sol-Gel Technologies's current ratio of this year was 4.37058824. Sol-Gel Technologies's current ratio of last year was 5.92173568.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Sol-Gel Technologies's number of shares in issue this year was 2.786. Sol-Gel Technologies's number of shares in issue last year was 2.786.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Sol-Gel Technologies's gross margin of this year was 1. Sol-Gel Technologies's gross margin of last year was 1.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Sol-Gel Technologies's asset turnover of this year was 0.48365612. Sol-Gel Technologies's asset turnover of last year was 0.26533905.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
1
+
0
+
1
+
0
+
1
=
6
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sol-Gel Technologies has an F-score of 6 indicating the company's financial situation is typical for a stable company.
Sol-Gel Technologies (STU:4SG) has a Piotroski F-Score of 6 as of Jul. 04, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sol-Gel Technologies and its competitors. This is 50% above median its historical median of 4.00. Over the past decade, Sol-Gel Technologies' Piotroski F-Score has ranged from 1.00 to 6.00. According to the industry distribution chart, Sol-Gel Technologies ranks #107 out of 1336 companies in the Biotechnology industry, placing it in the top 8%.
Is Sol-Gel Technologies' Piotroski F-Score too high?
Sol-Gel Technologies' current Piotroski F-Score of 6 is 50% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Sol-Gel Technologies' value of 6 is 100% above this industry median. Based on the distribution chart, Sol-Gel Technologies ranks #107 out of 1336 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sol-Gel Technologies has a GF Score™ of 55/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sol-Gel Technologies' Piotroski F-Score compare to AVXL and FATE?
According to the Biotechnology industry distribution chart, Sol-Gel Technologies ranks #107 out of 1336 companies for Piotroski F-Score. This places Sol-Gel Technologies in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Sol-Gel Technologies' value of 6 is 100% above this benchmark. Historically, Sol-Gel Technologies' own Piotroski F-Score has ranged from 1.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Sol-Gel Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,336 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sol-Gel Technologies's current Piotroski F-Score of 6 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sol-Gel Technologies and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sol-Gel Technologies's current Piotroski F-Score is 6, which is 50% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sol-Gel Technologies stock overvalued right now?
Based on GuruFocus' analysis, Sol-Gel Technologies (STU:4SG) is currently considered Modestly Overvalued. The stock's GF Value™ is €54.63, compared to a current price of €62.00 — trading 13.5% above its estimated fair value. The current Piotroski F-Score is 6, which is 50% above median its 10-year median of 4.00 and 100% above the Biotechnology industry median of 3.00. Sol-Gel Technologies' overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sol-Gel Technologies (STU:4SG), the current Piotroski F-Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sol-Gel Technologies (STU:4SG) Overvalued in 2026?
Based on GuruFocus' analysis, Sol-Gel Technologies stock appears to be overvalued.
The current stock price of €62.00 is trading 13.5% above its estimated GF Value™ of €54.63.
GuruFocus considers Sol-Gel Technologies to be Modestly Overvalued.
Key valuation signals for STU:4SG:
Piotroski F-Score: 6 (50% above median its 10-year median of 4.00)
GF Value™: €54.63 vs. price of €62.00 (13.5% above fair value)
Industry Position: 100% above the Biotechnology median (#107 of 1336)
No single metric tells the full story. See the STU:4SG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.
55GF Score
Get the complete analysis for STU:4SG
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:4SG has been successfully added to your 
